News
News
May 4, 2022
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
April 27, 2022
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
March 21, 2022
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
March 14, 2022
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
March 7, 2022
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
January 5, 2022
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference